Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced significant moves in its stock performance, attracting investor attention.

Sana’s HIP technology aims to eliminate the ... In three months, CytomX Therapeutics’ stock has lost 14.5%. CTMX’s earnings beat estimates in two of the trailing four quarters and missed ...

If you are looking for an AI stock that is more promising than SANA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 10 Hottest Mid ...

BofA Securities analysts, led by Geoff Meacham, reiterated their Buy rating on Sana Biotechnology stock, maintaining a price target of $7.00. InvestingPro data reveals that analyst targets range ...

Yet Sana’s stock price initially soared 200%. And even if experts weren’t quite as exuberant, some acknowledged the company and the field had potentially taken an important step forward.

Short interest in Sana Biotechnology Inc (NASDAQ:SANA) increased during the last reporting period, rising from 37.10M to 50.28M. This put 46.55% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...